

# Sahil B Seth

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/9373829/sahil-b-seth-publications-by-citations.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

50  
papers

34,426  
citations

37  
h-index

54  
g-index

54  
ext. papers

43,674  
ext. citations

28  
avg, IF

8.33  
L-index

#	Paper	IF	Citations
50	The Cancer Genome Atlas Pan-Cancer analysis project. <i>Nature Genetics</i> , <b>2013</b> , 45, 1113-20	36.3	3933
49	Comprehensive molecular characterization of gastric adenocarcinoma. <i>Nature</i> , <b>2014</b> , 513, 202-9	50.4	3659
48	Comprehensive molecular profiling of lung adenocarcinoma. <i>Nature</i> , <b>2014</b> , 511, 543-50	50.4	3310
47	Integrated genomic characterization of endometrial carcinoma. <i>Nature</i> , <b>2013</b> , 497, 67-73	50.4	2800
46	Comprehensive genomic characterization of head and neck squamous cell carcinomas. <i>Nature</i> , <b>2015</b> , 517, 576-82	50.4	2332
45	Comprehensive molecular characterization of urothelial bladder carcinoma. <i>Nature</i> , <b>2014</b> , 507, 315-22	50.4	1963
44	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 2481-98	59.2	1828
43	Genomic Classification of Cutaneous Melanoma. <i>Cell</i> , <b>2015</b> , 161, 1681-96	56.2	1807
42	The Molecular Taxonomy of Primary Prostate Cancer. <i>Cell</i> , <b>2015</b> , 163, 1011-25	56.2	1713
41	Integrated genomic characterization of papillary thyroid carcinoma. <i>Cell</i> , <b>2014</b> , 159, 676-90	56.2	1660
40	Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. <i>Cell</i> , <b>2016</b> , 164, 550-63	56.2	1140
39	Integrated genomic characterization of oesophageal carcinoma. <i>Nature</i> , <b>2017</b> , 541, 169-175	50.4	965
38	Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. <i>Cell</i> , <b>2014</b> , 158, 929-944	56.2	935
37	Integrated genomic and molecular characterization of cervical cancer. <i>Nature</i> , <b>2017</b> , 543, 378-384	50.4	755
36	Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. <i>Nature</i> , <b>2014</b> , 514, 628-32	50.4	727
35	Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. <i>Science</i> , <b>2014</b> , 346, 256-9	33.3	659
34	Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. <i>Journal of Biological Chemistry</i> , <b>2014</b> , 289, 3869-75	5.4	632

33	The somatic genomic landscape of chromophobe renal cell carcinoma. <i>Cancer Cell</i> , <b>2014</b> , 26, 319-330	24.3	521
32	Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. <i>Cancer Cell</i> , <b>2017</b> , 32, 204-220.e15	24.3	391
31	Mutational landscape of aggressive cutaneous squamous cell carcinoma. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 6582-92	12.9	362
30	A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. <i>Cancer Cell</i> , <b>2017</b> , 31, 820-832.e3	24.3	286
29	Systematic analysis of telomere length and somatic alterations in 31 cancer types. <i>Nature Genetics</i> , <b>2017</b> , 49, 349-357	36.3	277
28	Characterization of HPV and host genome interactions in primary head and neck cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, 15544-9	11.5	229
27	Evaluation and Design of Genome-Wide CRISPR/SpCas9 Knockout Screens. <i>G3: Genes, Genomes, Genetics</i> , <b>2017</b> , 7, 2719-2727	3.2	211
26	A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing. <i>Nature Communications</i> , <b>2015</b> , 6, 10001	17.4	199
25	Recurrent PTPRB and PLCG1 mutations in angiosarcoma. <i>Nature Genetics</i> , <b>2014</b> , 46, 376-379	36.3	196
24	Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma. <i>Nature Genetics</i> , <b>2018</b> , 50, 708-717	36.3	116
23	Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state. <i>Science Translational Medicine</i> , <b>2019</b> , 11,	17.5	93
22	Genomic heterogeneity of multiple synchronous lung cancer. <i>Nature Communications</i> , <b>2016</b> , 7, 13200	17.4	85
21	Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. <i>Journal of Clinical Investigation</i> , <b>2015</b> , 125, 1459-70	15.9	84
20	InVivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer. <i>Cell Reports</i> , <b>2016</b> , 16, 133-147	10.6	77
19	Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. <i>Nature</i> , <b>2019</b> , 568, 410-414	50.4	74
18	Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. <i>Nature</i> , <b>2017</b> , 542, 362-366	50.4	70
17	Systematic Epigenomic Analysis Reveals Chromatin States Associated with Melanoma Progression. <i>Cell Reports</i> , <b>2017</b> , 19, 875-889	10.6	53
16	Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. <i>Cancer Research</i> , <b>2015</b> , 75, 1091-101	10.1	53

15	High-resolution clonal mapping of multi-organ metastasis in triple negative breast cancer. <i>Nature Communications</i> , <b>2018</b> , 9, 5079	17.4	52
14	A Pan-Cancer Compendium of Genes Deregulated by Somatic Genomic Rearrangement across More Than 1,400 Cases. <i>Cell Reports</i> , <b>2018</b> , 24, 515-527	10.6	49
13	Pre-existing Functional Heterogeneity of Tumorigenic Compartment as the Origin of Chemoresistance in Pancreatic Tumors. <i>Cell Reports</i> , <b>2019</b> , 26, 1518-1532.e9	10.6	36
12	Somatic mutation distributions in cancer genomes vary with three-dimensional chromatin structure. <i>Nature Genetics</i> , <b>2020</b> , 52, 1178-1188	36.3	25
11	Functional Genomics Reveals Synthetic Lethality between Phosphogluconate Dehydrogenase and Oxidative Phosphorylation. <i>Cell Reports</i> , <b>2019</b> , 26, 469-482.e5	10.6	25
10	Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib. <i>Cancer Research</i> , <b>2020</b> , 80, 4840-4853	10.1	17
9	Global impact of somatic structural variation on the DNA methylome of human cancers. <i>Genome Biology</i> , <b>2019</b> , 20, 209	18.3	9
8	Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> ,	12.9	5
7	Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer. <i>Gastroenterology</i> , <b>2021</b> , 161, 196-210	13.3	5
6	Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function. <i>Nature Communications</i> , <b>2021</b> , 12, 6340	17.4	2
5	Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma		2
4	Medium-Chain Acyl-CoA Dehydrogenase Protects Mitochondria from Lipid Peroxidation in Glioblastoma. <i>Cancer Discovery</i> , <b>2021</b> , 11, 2904-2923	24.4	2
3	Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a novel gain of function		1
2	The cytosolic iron-sulfur cluster assembly (CIA) pathway is required for replication stress tolerance of cancer cells to Chk1 and ATR inhibitors. <i>Npj Breast Cancer</i> , <b>2021</b> , 7, 152	7.8	0
1	A functional genomic approach to actionable gene fusions for precision oncology.. <i>Science Advances</i> , <b>2022</b> , 8, eabm2382	14.3	0